Bivalirudin as alternative to both danaparoid and heparin in off-pump coronary artery bypass grafting [6] (multiple letters)

Journal of Thoracic and Cardiovascular Surgery

Volumn 126, Issue 6, 2003, Pages 2108-2109

  Baciewicz Jr , Frank A ^a   Carrier, Michel ^b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MONTREAL HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; CROSS REACTING ANTIBODY; DANAPAROID; HEPARIN; HEPARIN ANTIBODY; HIRULOG; THROMBOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ANTICOAGULATION; BLEEDING; BLOOD CLOTTING TIME; CORONARY ARTERY BYPASS GRAFT; CROSS REACTION; DRUG HALF LIFE; HEART VALVE REPLACEMENT; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LETTER; LOW DRUG DOSE; OFF PUMP CORONARY SURGERY; PRIORITY JOURNAL; PROSPECTIVE STUDY; THROMBOCYTOPENIA;

EID: 0347064240     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5223(03)01309-6     Document Type: Letter

References (2)

1. M. Carrier D. Robitaille L.P. Perrault M. Pellerin P. Page R. Cartier Heparin versus danaparoid in off-pump coronary bypass grafting results of a prospective randomized clinical trial J Thorac Cardiovasc Surg 125 2003 325 329
2. J.C. Vasquez A. Vichiendilokkul S. Mahmood F.A. Baciewicz Anticoagulation with bivalirudin during cardiopulmonary bypass in cardiac surgery Ann Thorac Surg 74 2002 2177 2179